Co-Diagnostics Taps Molecular Diagnostics Veteran as CSO
Event summary
- Co-Diagnostics appointed Wes Lindsey, PhD, MBA as Chief Scientific Officer on July 16, 2026.
- Lindsey brings over 20 years of experience in molecular diagnostics, including leading teams through FDA clearance processes.
- The hire is aimed at supporting regulatory submissions for the Co-Dx PCR platform and pipeline expansion.
The big picture
Co-Diagnostics' appointment of a seasoned molecular diagnostics executive underscores the strategic importance of regulatory expertise as it seeks to commercialize its PCR platform. The move comes amid growing competition in the point-of-care diagnostics space, where FDA clearance remains a critical differentiator. Lindsey's track record suggests Co-Diagnostics is prioritizing scalable product development over near-term revenue growth.
What we're watching
- Regulatory Progress
- How quickly the Co-Dx PCR platform advances through FDA review under Lindsey's leadership.
- Pipeline Expansion
- Whether Lindsey can accelerate the development of new diagnostic tests for the company's pipeline.
- Commercialization Timing
- The pace at which Co-Diagnostics can bring its at-home and point-of-care diagnostics to market.